Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb: Plans to take a $15 mil. pre-tax restructuring charge in the second quarter as part of its ongoing expense-reduction program, the firm announces July 2. Roughly $5.5 mil. of the charge will go toward consolidation of B&L's 14 European distribution centers for contact lenses, solutions and sunglasses into three facilities over the next 16 months beginning in July. About $1.9 mil. will go toward reorganization of Asia-Pacific operations by dividing the business segment into North and South regions, B&L says. Formation of the previously planned "global vision care business" will cost $3.6 mil. ("The Gray Sheet" June 24, In Brief) and another $4 mil. will go toward "miscellaneous actions." In addition to the restructuring charge, B&L says it "will incur one-time period costs in the range of $5 mil. during the second half of 1996." Second quarter results are expected to be released July 18...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel